

Susanna Proudman Fracp

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3854639/susanna-proudman-fracp-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

3,503
citations

33
h-index

53
g-index

167
ext. papers

4,411
ext. citations

3.9
avg, IF

5.06
L-index

#	Paper	IF	Citations
158	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 53, 151973	5.3	0
157	Change in calcinosis over 1 year using the scleroderma clinical trials consortium radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 53, 151980	5.3	1
156	Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 103	5.7	0
155	Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 983-989	4.7	4
154	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology</i> , 2021 , 3, e844-e854	14.2	2
153	Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021 , 23, 22	6.9	2
152	Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2021 , 10, e015816	6	2
151	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
150	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 495-512	5.3	3
149	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021 , 160, 2158-2162	5.3	1
148	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 640-643	5.3	2
147	Patient satisfaction and acceptability with telehealth at specialist medical outpatient clinics during the COVID-19 pandemic in Australia. <i>Internal Medicine Journal</i> , 2021 , 51, 1028-1037	1.6	5
146	Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. <i>Arthritis Care and Research</i> , 2021 , 73, 732-741	4.7	8
145	Scleroderma renal crisis: observations from the South Australian Scleroderma Register. <i>Internal Medicine Journal</i> , 2021 , 51, 235-242	1.6	1
144	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021 , 140, 110314	4.1	3
143	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a multicohort analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211009020	3.8	1
142	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1108-1112	5.3	2

141	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 142-148	2.2	
140	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 142-148	2.2	0
139	Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020 , 2, 371-377	3.5	2
138	Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020 , 47, 1746-1751	4.1	1
137	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 891-896	5.3	6
136	Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy 2020 , 8,		9
135	Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care. <i>Internal Medicine Journal</i> , 2020 , 50, 1067-1072	1.6	3
134	Systemic sclerosis: Advances towards stratified medicine. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020 , 34, 101469	5.3	3
133	Consensus statements for managing systemic sclerosis-associated interstitial lung disease. <i>Lancet Rheumatology, The</i> , 2020 , 2, e64-e65	14.2	
132	Aberrant Expression of High Mobility Group Box Protein 1 in the Idiopathic Inflammatory Myopathies. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 226	5.7	6
131	Left ventricular ischemia in pre-capillary pulmonary hypertension: a cardiovascular magnetic resonance study. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1280-1292	2.6	1
130	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020 , 139, 110262	4.1	13
129	The clinical and economic burden of systemic sclerosis related interstitial lung disease. <i>Rheumatology</i> , 2020 , 59, 1878-1888	3.9	4
128	Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. <i>Internal Medicine Journal</i> , 2020 , 50, 818-822	1.6	1
127	Interstitial pneumonia with autoimmune features in a patient with melanoma differentiation-associated gene 5 (MDA5) antibody. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	
126	Performance of the 2017 EUSTAR activity index in an scleroderma cohort. <i>Clinical Rheumatology</i> , 2020 , 39, 3701-3705	3.9	0
125	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020 , 139, 110262	4.1	9
124	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>Scientific Reports</i> , 2020 , 10, 18634	4.9	3

123	Occupational silica exposure in an Australian systemic sclerosis cohort. <i>Rheumatology</i> , 2020 , 59, 3900-3905	3.5	6
122	Scleroderma in Cairns: an epidemiological study. <i>Internal Medicine Journal</i> , 2020 , 50, 445-452	1.6	2
121	Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72, 1625-1635	4.7	7
120	Can Patient-Reported Symptoms Be Used to Measure Disease Activity in Systemic Sclerosis?. <i>Arthritis Care and Research</i> , 2020 , 72, 1459-1465	4.7	6
119	Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges. <i>Heart Lung and Circulation</i> , 2020 , 29, 1459-1468	1.8	
118	Silicone breast implants and depression, fibromyalgia and chronic fatigue syndrome in a rheumatology clinic population. <i>Clinical Rheumatology</i> , 2019 , 38, 1271-1276	3.9	12
117	Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13375	2.9	8
116	The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 373-376	5.3	7
115	Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension: alternative scenario analyses. <i>Internal Medicine Journal</i> , 2019 , 49, 781-785	1.6	3
114	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 807-816	2.4	16
113	Defining primary systemic sclerosis heart involvement: A scoping literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 874-887	5.3	16
112	Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies. <i>Rheumatology International</i> , 2019 , 39, 1777-1781	3.6	9
111	Cardiac involvement in idiopathic inflammatory myopathies detected by cardiac magnetic resonance imaging. <i>Clinical Rheumatology</i> , 2019 , 38, 3471-3476	3.9	8
110	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. <i>Scientific Reports</i> , 2019 , 9, 14834	4.9	11
109	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019 , 10, 4955	17.4	46
108	The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. <i>BMC Pulmonary Medicine</i> , 2019 , 19, 226	3.5	2
107	Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. <i>Arthritis Research and Therapy</i> , 2019 , 21, 299	5.7	12
106	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019 , 46, 78-84	4.1	7

105	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
104	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. <i>Rheumatology</i> , 2019 , 58, 636-644	3.9	18
103	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 563-570	2.4	31
102	Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. <i>Rheumatology</i> , 2018 , 57, 73-83	3.9	13
101	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36
100	Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. <i>Clinical Rheumatology</i> , 2018 , 37, 1563-1571	3.9	8
99	Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. <i>Heart Lung and Circulation</i> , 2018 , 27, 1368-1375	1.8	17
98	Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018 , 20, 85	5.7	50
97	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. <i>PLoS ONE</i> , 2018 , 13, e0192704	3.7	57
96	The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders. <i>Blood</i> , 2018 , 132, 3081-3081	2.2	
95	Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2018 , 2, rky029	1.1	2
94	Risk factors for the development of systemic sclerosis: a systematic review of the literature. <i>Rheumatology Advances in Practice</i> , 2018 , 2, rky041	1.1	6
93	Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 53-60	2.2	6
92	The role of inflammatory markers in assessment of disease activity in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 126-134	2.2	9
91	Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. <i>Rheumatology International</i> , 2017 , 37, 897-904	3.6	16
90	Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. <i>Internal Medicine Journal</i> , 2017 , 47, 112-115	1.6	5
89	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. <i>Arthritis Research and Therapy</i> , 2017 , 19, 42	5.7	37
88	The utility of monitoring peripheral blood lymphocyte subsets by flow cytometric analysis in patients with rheumatological diseases treated with rituximab. <i>Autoimmunity Reviews</i> , 2017 , 16, 542-547 ^{13.6}		4

87	CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression. <i>Journal of Immunology</i> , 2017 , 198, 4490-4501	5.3	46
86	Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017 , 36, 791-798	3.9	2
85	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017 , 44, 799-805	4.1	14
84	Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 481-488	2.3	11
83	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1067-1077	9.5	91
82	Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 576-583	2.3	6
81	Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1447-1456	2.3	6
80	Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. <i>PLoS ONE</i> , 2017 , 12, e0183928	3.7	20
79	Early Accrual of Organ Damage in Systemic Sclerosis: Rationale for Development of a Disease Damage Index. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 127-134	2.3	3
78	Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 188-195	2.3	4
77	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1889-1893	4.1	12
76	Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration. <i>Drug Metabolism and Disposition</i> , 2017 , 45, 8-16	4	7
75	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1795-1797	2.3	1
74	A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1728-1750	2.3	10
73	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2017 , 19, 122	5.7	33
72	Measures of disease status in systemic sclerosis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 473-487	5.3	13
71	Dysregulated innate immune function in the aetiopathogenesis of idiopathic inflammatory myopathies. <i>Autoimmunity Reviews</i> , 2017 , 16, 87-95	13.6	16
70	Quantifying the direct public health care cost of systemic sclerosis: A comprehensive data linkage study. <i>Medicine (United States)</i> , 2017 , 96, e8503	1.8	8

69	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 169-182	2.3	11
68	Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 130-137	2.2	2
67	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2016 , 43, 1643-9	4.1	8
66	The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 246	5.7	10
65	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016 , 68, 167-78	4.7	10
64	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 344-349	5.3	48
63	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 299-311	9.5	69
62	Reduced corticosteroid-binding globulin cleavage in active rheumatoid arthritis. <i>Clinical Endocrinology</i> , 2016 , 85, 369-77	3.4	7
61	Immunomodulatory properties of mesenchymal stem cell in experimental arthritis in rat and mouse models: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 1-19	5.3	20
60	Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 23-9	2.4	73
59	Subsets in systemic sclerosis: one size does not fit all. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 298-306	2.3	7
58	Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. <i>Medical Journal of Australia</i> , 2016 , 204, 64-8	4	11
57	Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. <i>Arthritis Care and Research</i> , 2016 , 68, 1616-1623	4.7	24
56	A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 1046-57	3.8	1
55	Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. <i>BMJ Open</i> , 2016 , 6, e011028	2.8	9
54	Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. <i>BMC Pulmonary Medicine</i> , 2016 , 16, 134	3.5	25
53	Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 113-23	3.8	17
52	Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 170-176	2.2	11

51	The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 129-136	2.2	4
50	Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 79-84	2.2	7
49	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 7	5.7	63
48	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 411-23	2.8	11
47	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015 , 42, 2168-71	4.1	99
46	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 777-88	3.8	4
45	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. <i>Arthritis Research and Therapy</i> , 2015 , 17, 48	5.7	18
44	Synovial fluid and plasma n3 long chain polyunsaturated fatty acids in patients with inflammatory arthritis. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2015 , 97, 7-12	2.8	8
43	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. <i>Autoimmunity</i> , 2015 , 48, 542-51	3	18
42	Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 89-95	2.4	104
41	Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 421-32	2.3	10
40	Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis. <i>British Journal of Nutrition</i> , 2015 , 114, 885-90	3.6	22
39	Musculoskeletal Manifestations of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 507-18	2.4	29
38	Is there evidence indicating a link between periodontitis and rheumatoid arthritis?. <i>International Journal of Clinical Rheumatology</i> , 2015 , 10, 215-218	1.5	
37	Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S111-6	2.2	37
36	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S131-5	2.2	22
35	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014 , 53, 1172-7	3.9	58
34	Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 113-22	5.3	82

33	Individualization of leflunomide dosing in rheumatoid arthritis patients. <i>Personalized Medicine</i> , 2014 , 11, 449-461	2.2	5
32	Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 222-38	3.9	48
31	Effect of Porphyromonas gingivalis on citrullination of proteins by macrophages in vitro. <i>Journal of Periodontology</i> , 2013 , 84, 1272-80	4.6	14
30	Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1980-3	2.4	65
29	Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R213	5.7	66
28	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R163	5.7	37
27	Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1316-22		37
26	Pulsed intravenous cyclophosphamide for sle retinal vasculitis. <i>Retinal Cases and Brief Reports</i> , 2012 , 6, 111-5	1.1	1
25	Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2012 , 13, 1427-34	2.6	22
24	Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 55, 325-31	3.5	30
23	Fatty acid desaturase 2 promoter mutation is not responsible for β -desaturase deficiency. <i>European Journal of Human Genetics</i> , 2011 , 19, 1202-4	5.3	5
22	Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients. <i>Complementary Therapies in Medicine</i> , 2010 , 18, 171-4	3.5	27
21	Fish oil and rheumatoid arthritis: past, present and future. <i>Proceedings of the Nutrition Society</i> , 2010 , 69, 316-23	2.9	62
20	Epidemiology of systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 857-69	5.3	76
19	Eosinophilic fasciitis as a paraneoplastic phenomenon associated with metastatic colorectal carcinoma. <i>Australasian Journal of Dermatology</i> , 2008 , 49, 27-9	1.3	12
18	Dietary omega-3 fats for treatment of inflammatory joint disease: efficacy and utility. <i>Rheumatic Disease Clinics of North America</i> , 2008 , 34, 469-79	2.4	43
17	Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 562-71	4.1	40
16	Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 37, 99-111	5.3	58

15	Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1513-7	2.4	29
14	Fish oil: what the prescriber needs to know. <i>Arthritis Research and Therapy</i> , 2006 , 8, 202	5.7	68
13	Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. <i>Medical Journal of Australia</i> , 2006 , 184, 122-5	4	13
12	Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006 , 33, 1973-9	4.1	64
11	Lack of association of antineutrophil cytoplasmic antibodies with joint failure as indicated by joint surgery in rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2005 , 8, 54-59		
10	Omega-6/omega-3 fatty acids and arthritis. <i>World Review of Nutrition and Dietetics</i> , 2003 , 92, 152-68	0.2	12
9	A biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis. <i>Lipids</i> , 2003 , 38, 419-24	6	18
8	Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 64-71		398
7	Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3039-45		80
6	The role of fish oils in the treatment of rheumatoid arthritis. <i>Drugs</i> , 2003 , 63, 845-53	12.1	102
5	Predictors of outcome in patients with oligoarthritis: results of a protocol of intraarticular corticosteroids to all clinically active joints. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1177-83		40
4	Predictors of outcome in patients with oligoarthritis: Results of a protocol of intraarticular corticosteroids to all clinically active joints 2001 , 44, 1177		2
3	Accessible xenografts of human synovium in the subcutaneous tissues of the ears of SCID mice. <i>Immunology and Cell Biology</i> , 1999 , 77, 109-20	5	4
2	Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2184-8		128
1	Inhibition of human neutrophil leukotriene B4 synthesis in essential fatty acid deficiency: role of leukotriene A hydrolase. <i>Lipids</i> , 1994 , 29, 151-5	1.6	18